Probiotics Lifted Cognitive Scores by 39% in Elderly Stroke Survivors

A six-week course of probiotics may meaningfully improve cognitive function, motor recovery, and nutritional status in elderly survivors of ischemic stroke, according to a new retrospective cohort study published in Frontiers in Neurology. The research, led by Xiaohong Zheng and colleagues, tracked 223 patients over 60 years old through standard post-stroke care, with roughly half also receiving a daily probiotic supplement via nasogastric tube. The results suggest the gut-brain axis could be a meaningful lever in post-stroke rehabilitation, though the study design means causality cannot yet be confirmed.

Probiotic Supplementation Raised BDNF and Cognitive Test Scores

The supplement group received a triple-strain formulation containing Bifidobacterium longum R0175, Lactobacillus acidophilus R0052, and Enterococcus faecalis R0026, chosen for their documented effects on gut microbiota modulation, anti-inflammatory properties, and potential neuroprotection. By the end of the six-week period, patients taking the probiotic showed significantly higher levels of Brain-Derived Neurotrophic Factor (BDNF), a protein critical for neuronal survival and synaptic plasticity. BDNF is essentially a growth factor for the brain: it supports the formation of new connections and helps existing neurons survive under stress.

On the Mini-Mental State Examination (MMSE), a standard test of orientation, memory, and language, supplement group scores climbed from a mean of 19.03 to 26.51, a gain that reached statistical significance (p < 0.001). Scores on the Hasegawa Dementia Scale (HDS) rose from 9.34 to 15.26 (p = 0.002), while Clinical Dementia Rating (CDR) scores decreased, indicating improvement. The most pronounced gains appeared in memory-related items and tasks tied to motivation and self-care. Post-stroke cognitive impairment affects close to half of all first-time stroke patients, which puts the scale of the problem, and any potential intervention, in sharp relief.

Motor Function and Nutritional Markers Improved Alongside Cognition

Cognitive recovery did not happen in isolation. The Modified Barthel Index (MBI), which measures independence in basic daily activities like bathing, dressing, and mobility, rose from 39.23 to 63.87 in the supplement group (p = 0.004). Motor assessments using the Stroke Rehabilitation Assessment of Movement (STREAM) also showed significantly better upper and lower limb performance compared to the conventional group.

Nutritional indicators moved in step. Hemoglobin, albumin, and prealbumin all increased significantly in the probiotic group (p ≤ 0.011), suggesting that restoring gut microbial balance after stroke may help patients absorb and retain the nutrients needed for tissue repair and neurological function. Ischemic stroke frequently triggers gut dysbiosis, a disruption of the normal microbial community, which in turn worsens systemic inflammation and can undermine recovery on multiple fronts.

One practical benefit stood out: gastrointestinal adverse events occurred in only 12.3% of the probiotic group, compared to 32.5% in the conventional group (p < 0.001). For patients receiving enteral nutrition through a nasogastric tube, reducing nausea, bloating, and diarrhea is not a minor footnote; it directly affects how much nutrition they can absorb and how comfortable the recovery period is.

How the Study Was Designed and What It Can Show

The retrospective cohort drew on patient records from March 2021 through February 2024. Both groups received the same standard treatments: intracranial pressure reduction, nerve nourishment, infection control, and identical enteral nutrition emulsions. The only systematic difference was the probiotic supplement, which was administered through the nasogastric tube in the same sessions as enteral feeding. Baseline characteristics were well-matched, with no significant differences between the 117 conventional-care patients and the 106 supplement patients before treatment began.

The probiotic strains were selected in part for their capacity to produce short-chain fatty acids (SCFAs) such as butyrate, acetate, and propionate. SCFAs are thought to cross the blood-brain barrier and influence neuroinflammation, and they may also strengthen the intestinal lining, reducing the leakage of inflammatory molecules into the bloodstream. Other proposed mechanisms include modulating neurotransmitter synthesis and activating the vagus nerve, the long nerve that runs from the gut to the brainstem. Animal and in vitro studies have pointed to these anti-inflammatory and anti-oxidative pathways as plausible explanations for how probiotics might support neurological recovery. A separate meta-analysis of stroke-related microbiome research has similarly suggested probiotic supplementation can reduce infarct volume and improve cognitive performance, often through inflammatory modulation.

Key Limitations of This Retrospective Cohort

The study's retrospective design is its most significant constraint. Because data were collected from existing records rather than a prospectively randomized trial, it is impossible to rule out unmeasured confounders, and definitive causal claims cannot be made. The authors themselves note that randomized controlled trials are needed before these findings can change clinical practice.

The study also focused on BDNF as its primary marker of neuroplasticity while leaving other neurotrophins and inflammatory cytokines unmeasured, which means the biological picture is incomplete. It is also difficult to disentangle whether cognitive improvements reflect direct effects of probiotics on the brain or are partly mediated through better gastrointestinal health, improved nutrient absorption, or some combination. Individual variation in baseline gut microbiota, genetics, and the extent of stroke damage adds further complexity to interpreting the results. A systematic review of probiotic trials on cognition has noted that even across randomized studies the certainty of evidence remains low, calling for more rigorous investigation.

What Comes Next for Gut-Brain Interventions in Stroke Rehab

The findings from Zheng and colleagues add to a growing body of evidence suggesting that the gut microbiome is a plausible target in post-stroke care, not just a bystander. Identifying the optimal probiotic strains, doses, and treatment windows for elderly patients with varying degrees of stroke damage remains open work. So does the question of whether benefits extend beyond six weeks, and whether certain patient subgroups, defined by baseline microbiota composition or stroke severity, respond better than others.

For now, the data are encouraging but preliminary. A well-powered randomized controlled trial that also measures inflammatory cytokines, microbiome composition, and longer-term functional outcomes would do much to clarify whether adding a probiotic to standard enteral nutrition should become a routine part of stroke rehabilitation. Until then, the gut-brain axis remains one of the more promising, and still underexplored, angles in neurological recovery.

Evidence rating

EMERGING — 80/100

Caveats:

• Retrospective cohort design — participants were not randomly assigned, so unmeasured differences between groups could explain some results.
• Cannot establish causation: it is unclear how much of the benefit came from direct gut-brain signaling versus improved gastrointestinal tolerance enabling better nutrition absorption.
• No independent replication of these specific strains and doses in a stroke population; prospective RCT data are needed before clinical adoption.
• Funding source was not disclosed by the authors.

Retrospective cohort study (n=223) comparing standard enteral nutrition with or without a three-strain probiotic supplement over 6 weeks in elderly ischemic stroke survivors. The non-randomized design limits causal inference, and unmeasured confounding between the two treatment groups cannot be excluded. Results are consistent with prior mechanistic work on the gut-brain axis but have not yet been independently replicated in a prospective controlled trial.

References

1. Xiaohong Zheng, Wei Chen, Kai Hong, Jiaqing Chen, Yuebin Lin, Jiehua Yang (2026). The effect of probiotic supplements on cognitive outcomes and neuroplasticity in elderly ischemic stroke survivors. Frontiers in Neurology. https://doi.org/10.3389/fneur.2026.1833163
2. Incidence of cognitive impairment post first stroke: a systematic review and meta-analysis. NIH. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10904791/
3. Chatuthanai Savigamin, Chatpol Samuthpongtorn, Nuttida Mahakit, Tanawin Nopsopon, Julia Heath, Krit Pongpirul (2022). Probiotic as a Potential Gut Microbiome Modifier for Stroke Treatment: A Systematic Scoping Review of In Vitro and In Vivo Studies. Nutrients. https://doi.org/10.3390/nu14173661
4. Ischemic Stroke and the Microbiome: Exploring the Gut-Brain Link. NIH. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10355416/
5. Nancy Calzada-Gonzales, Ismael Moreno-Colina, Linn Chu-Fuentes, et al. (2025). Efficacy and safety of probiotic supplements on cognitive function: a systematic review and meta-analysis of randomized clinical trials. BMC Complementary Medicine and Therapies. https://doi.org/10.1186/s12906-025-05149-6